Podcast episode
Venture Secondaries Desk · 11:08 · 2026-07-12
This is a company that pioneered an entire surgical category back in 2012 and is now betting big on pharmaceuticals.
Transcript — free half of this episode
host: Welcome back to AskCyborg — I'm Alex. Today we're digging into Glaukos Corporation, a name that keeps popping up in eye care circles. With me, as always, James Wright, who watches product proof and market pull, and Sarah Miller, who watches cash conversion and defensibility. Let's get into it.
analyst2: So Glaukos, ticker GKOS, is basically the company that invented the micro-invasive glaucoma surgery category back in 2012. Their iStent and iStent infinite devices are tiny implants that improve eye fluid drainage, and now iDose TR adds a pharmaceutical delivery angle. Revenue's around $507 million, and they just guided 2026 net sales to $600 to $620 million. That's not incremental — that's a company telling you the growth story is still early.
analyst1: What stands out to me is the balance sheet discipline behind that growth story. A current ratio of 5.2 and debt-to-equity of just 0.14 — that's a company funding expansion without leaning on debt. In a device market where Alcon and Bausch and Lomb have far deeper pockets, that kind of financial conservatism is how a smaller innovator stays in the fight long-term.
analyst2: Right, and that discipline is exactly why the Q4 2025 preliminary numbers mattered — $143 million in sales, 36% year-over-year growth, with iDose TR contributing $45 million on its own. That's proof the newer product is actually converting, not just adding noise. If you want the full picture — the complete debate, the full Glaukos report, plus how it stacks up against Alcon and Bausch and Lomb — that's where this gets interesting.
host: Hold up — this is where it gets interesting. The FDA cleared Epioxa with a launch expected in Q1 2026, adding a third growth lever to watch. James and Sarah are about to weigh in with their full analysis — leadership, financials, risks, catalysts, all in the complete report. Remember, this is strategic business analysis, not investment advice. The full verdict is waiting. Let's unlock it.